MedTrace Logo

HSV529 Vaccine in HSV-2 Seropositive Adults

NCT02571166 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-01-14

No results posted yet for this study

Summary

The purpose of the study is to determine the safety of HSV529 vaccine in healthy volunteers with HSV infection and to determine if administration of the HSV529 vaccine increases the immune response in genital skin.

Conditions

  • Herpes Simplex Virus 2

Interventions

BIOLOGICAL

HSV529

Live, Replication-defective HSV-2 virus

DRUG

Valacyclovir

500 mg orally, once daily for 4 weeks

Sponsors & Collaborators

  • University of Washington

    collaborator OTHER

  • Sanofi Pasteur, a Sanofi Company

    collaborator INDUSTRY

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Christine Johnston, MD, MPH · University of Washington

  • Lawrence Corey, MD · Fred Hutchinson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-12-01
Completion
2018-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02571166 on ClinicalTrials.gov